Fate Therapeutics, Inc. Forecast, price target & analysts
Fate Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Fate Therapeutics, Inc. Classifications & Recommendation:
Fate Therapeutics, Inc. Price Target
| Target Price | $6.72 |
| Price | $1.25 |
| Potential |
437.78%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Fate Therapeutics, Inc. 2026 .
The average Fate Therapeutics, Inc. target price is $6.72.
This is
437.78%
register free of charge
$12.00
860.00%
register free of charge
$2.50
100.00%
register free of charge
|
|
| A rating was issued by 12 analysts: 4 Analysts recommend Fate Therapeutics, Inc. to buy, 8 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2026 of
437.78%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 13.63 | 3.83 |
| 78.55% | 71.93% | |
| EBITDA Margin | -1,295.52% | -5,310.67% |
| 416.57% | 309.92% | |
| Net Margin | -1,370.84% | -4,524.14% |
| 366.10% | 230.03% |
12 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2025 . The average Fate Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2025. The average Fate Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Fate Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.64 | -1.52 |
| 0.00% | 7.32% | |
| P/E | negative | |
| EV/Sales | negative |
13 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Fate Therapeutics, Inc....
Current Fate Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 22 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 22 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
